Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.61 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.39 |
| ▸ | ABL2 | P42684 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | PRKCG | P05129 | 1/20 | 0.35 |
| ▸ | PRKCB | P05771 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5186721 | 0.95 | TGFBR1 (0.60) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL2049297 | 0.84 | TGFBR1 (0.61) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL2045872 | 0.82 | TGFBR1 (0.68) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL2679359 | 0.82 | TGFBR1 (0.65) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL5187792 | 0.81 | TGFBR1 (0.60) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL2050975 | 0.81 | TGFBR1 (0.71) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL5091553 | 0.81 | TGFBR1 (0.71) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL5188286 | 0.80 | TGFBR1 (0.70) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL5278449 | 0.80 | TGFBR1 (0.67) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL5186668 | 0.79 | TGFBR1 (0.66) | TGFBR1MAPK14THRBTGFBR2ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2006-11-23 | — | — | US | claimed |
| EP-1596656-A4 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-10-18 | — | — | EP | claimed |
| JP-2006517592-A | — | — | 2006-07-27 | — | — | JP | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1596656-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004072033-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-08-26 | — | — | WO | claimed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-RE39423-E1 | Optical fiber coating composition and method of preparing a cured coating composition | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2006-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | ALK, ACVR1, ALKBH5 | TGFBR1 26/4885MAPK14 1842/4885THRB 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.